Anticancer Drugs Mesna Oncology Pharmacology Physiotherapy

Intravenous Mesna

In this article we will discuss Intravenous Mesna

In this article, we will discuss Intravenous Mesna. So, let’s get started.

Intravenous Mesna

Hemorrhagic cystitis produced by ifosfamide is dose dependent (Table 4). At a dose of 1.2 g/m2 ifosfamide administered daily for 5 days, 16 to 26% of the patients who received conventional uroprophylaxis (high fluid intake, alkalinization of the urine, and the administration of diuretics) developed hematuria (>50 RBC per hpf or
macrohematuria) (Studies 1, 2, and 3). In contrast, none of the patients who received mesna injection together with this dose of ifosfamide developed hematuria (Studies 3 and 4). In two randomized studies, (Studies 5 and 6), higher doses of ifosfamide, from 2 g/m2 to 4 g/m2 administered for 3 to 5 days, produced hematuria in 31 to 100% of the patients. When Mesna was administered together with these doses of ifosfamide, the incidence of hematuria was less than 7%.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.